Login

Journal Image
Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)
ISSN (Print): 1871-529X
ISSN (Online): 2212-4063
VOLUME: 14
ISSUE: 1
DOI: 10.2174/1871529X1401140724094846









Atrial Fibrillation – New Frontiers in Anticoagulation

img
Author(s): Ranji Thomas, Pierre Le Page and Andrew R.J. Mitchell
Pages 45-49 (5)
Abstract:
Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.
Keywords:
Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.
Affiliation:
Department of Cardiology, Jersey General Hospital, Gloucester Street, St Helier, Jersey, JE1 3QS.